(81 days)
For light curing polymerization of dental composites, luting materials, cements and other light cured materials.
Not Found
This document is a 510(k) clearance letter from the FDA for a dental light-curing device called "Bluephase 16i." It certifies that the device is substantially equivalent to legally marketed predicate devices.
The letter does not contain any information about acceptance criteria or a study that proves the device meets specific performance criteria.
Therefore, I cannot provide the requested information. The document focuses on regulatory clearance based on substantial equivalence, not on a detailed presentation of performance studies against acceptance criteria.
{0}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/0/Picture/1 description: The image shows the seal of the Department of Health and Human Services (HHS) of the United States. The seal features the department's name encircling a stylized caduceus symbol. The caduceus is a symbol of medicine and health, and it is depicted with a staff entwined by two snakes.
Public Health Service
SEP 2 1 2005
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Ms. Donna M. Hartnett Assistant Corporate Counsel Ivoclar Vivadent, Incorporated 175 Pineview Drive Amherst, New York 14228
Re: K051782
Trade/Device Name: Bluephase 16i Regulation Number: 21 CFR 872.6070 Regulation Name: Ultraviolet Activator for Polymerization Regulatory Class: II Product Code: EBZ Dated: June 24, 2005 Received: July 7, 2005
Dear Ms. Hartnett:
This letter corrects our substantially equivalent letter of September 20, 2005, regarding the 510 (K) Number.
We have reviewed your Section 510(k) premarket notification of intent to market the device we have reviewed your becatermined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device mensiale connineree pror to that have been reclassified in accordance with the provisions of Amendinents, on to de roos alla have - Act (Act) that do not require approval of a premarket the rederal I vou, Drug, and Commay, therefore, market the device, subject to the general approvisions of the Act. The general controls provisions of the Act include controls provisions of the vistration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting (FMA), it may oc subject to back adalaf Federal Regulations, Title 21, Parts 800 to 898. In your device can oc found in the South nonements concerning your device in the Federal Register.
{1}------------------------------------------------
Page 2 - Ms. Hartnett
Please be advised that FDA's issuance of a substantial equivalence determination does not Please be advised that PDA S issualled of a babeanant is vice complies with other requirements mean that IDA has made a deceminations administered by other Federal agencies. of the Act of ally I ederal statutes and regarations, but not limited to: registration You must comply with an the Het STS Part 801); good manufacturing practice and ifsiling (21 CFR Part 607), laceming (21 CFR Part 820), regulation (21 CFR Part 820), and if requirements as set form in the quality bysteins (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) This letter will anow you to begin maticolary your device of your device to a a premarket notification. The PDF Intellig on classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), If you desire specific advice for your de rocked in the Also, please note the regulation in entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Illay obtain of Small Manufacturers, International and Consumer Assistance at its toll-free Diviser (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Clurs
Chiu Lin, Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
K051782_______________________________________________________________________________________________________________________________________________________________________ 510(k) Number (if known):
Device Name: bluephase 16i
Indications For Use:
For light curing polymerization of dental composites, luting materials, cements
on and and and color and other light cured materials.
Prescription Use & L AND/OR (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE) Page 1 of ____________________________________________________________________________________________________________________________________________________________________
Susan Runne
(Division Sign-Off) (Division Sign-Olf)
Division of Anesthesiology, General Hospital,
Division of Anesthesiology, General Devices Division of Anesthoulorology, Infection Control, Devices
510(k) Number. K051782
§ 872.6070 Ultraviolet activator for polymerization.
(a)
Identification. An ultraviolet activator for polymerization is a device that produces ultraviolet radiation intended to polymerize (set) resinous dental pit and fissure sealants or restorative materials by transmission of light through a rod.(b)
Classification. Class II.